{"schema_version":"secwatch.filing_event.v1","accession":"0000879407-26-000058","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2026-08-04T20:03:02+00:00","discovered_at":"2026-08-04T20:04:00.992586+00:00","generated_at":"2026-08-04T20:04:53.967290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arrowhead Q3 revenue $75.3M; plozasiran Phase 3 hits endpoints; Madrigal license deal","bullets":["Revenue $75.3M (up 171% YoY); net loss $194.3M ($1.36 diluted EPS) vs $175.2M ($1.26) prior year.","Plozasiran Phase 3 SHASTA-3/4: 79% and 81% median triglyceride reductions; 78% reduction in acute pancreatitis events.","Acquired FDA priority review voucher for plozasiran sNDA in sHTG, expected before end of 2026.","Exclusive license to Madrigal for ARO-PNPLA3: $25M upfront, up to $975M milestones, tiered royalties.","REDEMPLO prescriptions roughly doubled in Q3; >400 prescribers; EU and Australia marketing authorizations."],"urls":{"canonical":"https://secwatch.observer/filing/0000879407-26-000058","json":"https://secwatch.observer/filing/0000879407-26-000058.json","markdown":"https://secwatch.observer/filing/0000879407-26-000058.md","text":"https://secwatch.observer/filing/0000879407-26-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000058/0000879407-26-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000058/arwr-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:04:53.967290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}